**Mechanism of Action**

**Dostarlimab**
- Dostarlimab is a programmed death 1 (PD-1)-blocking antibody that binds to PD-1 and effectively blocks the interaction with the PD-1-Ligands 1 and 2 (PD-L1 and PD-L2).
- Dostarlimab is approved as a monotherapy in adult patients with mismatch repair deficient (dMMR) or dMMR/microsatellite instability-high (dMMR/MSS) EC or recurrent or advanced endometrial cancer (EC) that has progressed on or after prior treatment with a platinum-containing regimen.
- Dostarlimab approval was based on positive results from the phase 1 GARNET trial, which demonstrated the antitumor activity of dostarlimab in patients with dMMR/MH EC endometrial cancer.

**Niraparib**
- Niraparib is an orally available inhibitor of the poly(ADP-ribose) polymerase (PARP) enzymes PARP-1 and PARP-2, which play a role in DNA repair.
- Niraparib is approved as maintenance therapy in the first-line and recurrent settings in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are considered responsive to platinum-based chemotherapy.

**Trial Design for RUBY Part 2**

**Primary endpoint**
- Compare PFS evaluated by blinded independent review committee per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

**Secondary endpoints**
- PFS by investigator assessment
- Overall survival
- Objective response rate
- Duration of response
- Disease control rate
- PFS-2
- Patient-reported outcomes for quality of life assessment

**Enrolling Countries**
- Belarus (CEGOG)
- Denmark (NSGO-CTU)
- Greece (NSGO)
- Italy (MTO)
- Poland (NSGO)
- Turkey (NSGO)
- Belgium (BFCOG)
- Finland (NSGO-CTU)
- Hungary (CEGO)
- Netherlands (NSGO-CTU)
- Spain (CEGO)
- Sweden (NSGO-CTU)
- United Kingdom (NCRI)
- Czech Republic (CEGOG)
- Germany (AGO)
- Israel (ISG)
- Norway (NSGO-CTU)

**Summary**
- **RUBY** is a randomized, double-blind, placebo-controlled, multicenter phase 3 study of dostarlimab in patients with recurrent or primary advanced EC who are eligible.
- **-key inclusion criteria**
  - Patients with recurrent or primary advanced EC are eligible.
  - All histologies (including carcinomas) are eligible.
- **Key exclusion criteria**
  - Patients with primary advanced EC disease must not have received prior radiation or chemotherapy.
  - Patients with another malignancy treated by curative intent within the last 5 years.
  - Patients with a performance status of 3 or 4.
  - Patients with uncontrolled hypertension.
  - Patients with a history of severe or uncontrolled infection.
  - Patients with active central nervous system (CNS) disease.
  - Patients with a history of malignancy.
  - Pregnant or breastfeeding women.
  - Participation in other clinical trials or investigational therapies within 30 days or five half-lives of enrollment.

**References**
- Frontiers in Oncology 2018;8:677.
- Curr Opin Oncol 2019;31:S1166-S1168.

**Conclusion of Interest**
- No relationships reported.
- No funding sources reported.
- No potential conflicts of interest reported.

**Presented at the European Society for Medical Oncology (ESMO) Virtual Congress, September 16-21, 2021**